Melanoma Immunotherapy
Mural Oncology Inc. is involved in clinical research for advanced cutaneous melanoma and advanced mucosal melanoma, with a therapeutic focus on immuno-oncology approaches centered on nemvaleukin alfa and its use alone or with pembrolizumab.
- Advanced cutaneous melanoma
- Advanced mucosal melanoma
- Nemvaleukin alfa
- Pembrolizumab
The sponsor’s melanoma portfolio reflects interest in tumor response assessment and immune-based cancer treatment for difficult-to-treat melanoma subtypes.
Ovarian Cancer and Related Gynecologic Malignancies
The company also funds research in platinum-resistant epithelial ovarian cancer, including fallopian tube cancer and primary peritoneal cancer, with attention to combination treatment strategies involving nemvaleukin alfa and pembrolizumab.
- Platinum-resistant epithelial ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer
- Combination immunotherapy
Its gynecologic oncology activity is directed toward survival outcomes and treatment options for disease with limited standard responses.
